CORD-19:0329e0f2e3b8ab0eabe2afe0e5214cc88c61080e / 20271-20441 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/0329e0f2e3b8ab0eabe2afe0e5214cc88c61080e","sourcedb":"CORD-19","sourceid":"0329e0f2e3b8ab0eabe2afe0e5214cc88c61080e","text":"Notably, as a broad spectrum anti-RNA virus drug, favipiravir has been submitted for additional indications for SFTS in Japan, based on clinical trials (Yasukawa, 2016) .","tracks":[{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T113","span":{"begin":0,"end":170},"obj":"Sentence"},{"id":"T4018","span":{"begin":0,"end":170},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"TextSentencer_T113","pred":"source","obj":"CORD-19-Sentences"},{"subj":"T4018","pred":"source","obj":"CORD-19-Sentences"}]},{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T113","span":{"begin":0,"end":170},"obj":"Sentence"}],"attributes":[{"subj":"T113","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"Epistemic_Statements","denotations":[{"id":"T29","span":{"begin":0,"end":170},"obj":"Epistemic_statement"}],"attributes":[{"subj":"T29","pred":"source","obj":"Epistemic_Statements"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19-Sentences","color":"#93caec","default":true},{"id":"CORD-19_Custom_license_subset","color":"#e4ec93"},{"id":"Epistemic_Statements","color":"#da93ec"}]}]}}